ArticleAntimicrobial resistance and infection control2025
Clinical risk factors associated with nosocomial Pseudomonas aeruginosa bacteraemia in patients within a tertiary care healthcare setting - a case control study.
Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundP. aeruginosa is a major cause of hospital-acquired infections, particularly in healthcare settings in the UK and Europe. In 2017, the number of patients with P. aeruginosa bacteraemia in a London teaching hospital was increasing and demographic studies had attempted to identify the cause. A case–control study was undertaken with the aim to determine the pre-existing risk factors for developing P. aeruginosa bacteraemia among hospital inpatients, many of whom were immunocompromised.
methodsMultivariable, matched, case-control analysis using conditional logistic regression was performed to determine the risk factors associated with acquisition of P. aeruginosa bacteraemia at a tertiary care teaching hospital (800 patient beds; 98 beds for haematology patients) in London, UK. The cases were 137 patients with hospital-onset P. aeruginosa detected in blood and two control groups comprising a total of 845 patients (treated between April 2015 – July 2018). The analysis included the following predictor variables: admission method, blood test results, known viral infection, presence of central lines, surgical history, urinary tract infection and P. aeruginosa detected in urine, wound, or respiratory system. SPSS and R were used for the statistical analysis.
resultsOf 135 patients with bacteraemia due to Pseudomonas aeruginosa, 23 (17%) died within 30 days compared with 20 (4.1%) of 488 matched patients with no bacteraemia and 24 (6.7%) of 357 patients with other causes of bacteraemia. Analysis showed white cell count ≤ 2 × 109/L was associated with increased risk of pseudomonas bacteraemia (Adj. OR = 3.3 (1.6–6.6 ; p < 0.001) vs. patients with other causes of bacteraemia. Presence of P aeruginosa in urine or respiratory secretions and number of central venous catheters were associated with Adj. OR 19.3 (95% CI: 3.0-122 ; p = 0.02), 23.0 (95% CI: 2.3-226.3 ; p = 0.007 and 2.0 (95% CI: 1.17–3.37 ; p = 0.01) respectively.
conclusionsThis study showed leucopenia, having more than one central-venous catheter, P. aeruginosa urinary and respiratory infection, non-elective admission to hospital, and presence of virus were risk factors for P. aeruginosa bacteraemia. In healthcare settings where P. aeruginosa bacteraemia is prevalent, additional screening for carriage and treatment of bacteriuria with P. aeruginosa should be considered during hospital admission with an aim to prevent bacteraemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.